ETF Building Blocks Channel Consolidation Could Come Calling for Biotech in 2022 By Tom LydonJanuary 5, 2022
ETF Building Blocks Channel Memeification of Biotech Stocks Shines Light on This ETF By Tom LydonNovember 24, 2021
Innovative ETFs Channel Pfizer’s COVID-19 Pill Has Mixed Results for Healthcare ETFs By Max ChenNovember 5, 2021
ETF Building Blocks Channel Biotech Ready to Participate in Healthcare Bullishness By Tom LydonOctober 29, 2021
ETF Building Blocks Channel Drug Price Debate May Not Hinder Biotech ETFs After All By Tom LydonSeptember 16, 2021
ETF Building Blocks Channel Biotech Stocks Have Colds, but They Can Heal By Tom LydonSeptember 13, 2021
Innovative ETFs Channel Moderna Vaccine Is Granted Authorization in Australia By Max ChenAugust 9, 2021
Beyond Basic Beta Channel Mostly Sanguine Regulatory Outlook for Biotech, Healthcare Names By Tom LydonJuly 30, 2021
ETF Building Blocks Channel Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
Beyond Basic Beta Channel Changing FDA Regulatory Environment Could Bolster Biotech, ‘BBH’ By Tom LydonJuly 1, 2021
ETF Building Blocks Channel Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
Innovative ETFs Channel Will Biotech ETFs Benefit from Biogen’s New Alzheimer’s Drug? By Ian YoungJune 9, 2021
